Allergic contact dermatitis (ACD) is a common skin disease that results in significant cost and morbidity. Despite its high prevalence, therapeutic options are limited. Allergic contact dermatitis is regulated primarily by T cells within the adaptive immune system, but also by natural killer and innate lymphoid cells within the innate immune system. The chemokine receptor system, consisting of chemokine peptides and chemokine G protein–coupled receptors, is a critical regulator of inflammatory processes such as ACD. Specific chemokine signaling pathways are selectively up-regulated in ACD, most prominently CXCR3 and its endogenous chemokines CXCL9, CXCL10, and CXCL11. Recent research demonstrates that these 3 chemokines are not redundant and indeed activate distinct intracellular signaling profiles such as those activated by heterotrimeric G proteins and β-arrestin adapter proteins. Such differential signaling provides an attractive therapeutic target for novel therapies for ACD and other inflammatory diseases.
Get full access to this article
View all access options for this article.
References
1.
LimHW, CollinsSAB, ResneckJSJr, et al.The burden of skin disease in the United States. J Am Acad Dermatol, 2017; 76:958–972.
2.
VerhagenJ, AkdisM, Traidl-HoffmannC, et al.Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol, 2006; 117:176–183.
3.
LusterAD, AlonR, von AndrianUH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol, 2005; 6:1182–1190.
4.
HomeyB, SteinhoffM, RuzickaT, et al.Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol, 2006; 118:178–189.
5.
KobayashiY, StaquetMJ, Dezutter-DambuyantC, et al.Development of motility of Langerhans cell through extracellular matrix by in vitro hapten contact. Eur J Immunol, 1994; 24:2254–2257.
6.
CruzPD. What accounts for contact allergy?. Dermatitis, 1994; 5:189–193.
7.
NosbaumA, VocansonM, RozieresA, et al.Allergic and irritant contact dermatitis. Eur J Dermatol, 2009; 19:325–332.
8.
CamposRA, SzczepanikM, LisbonneM, et al.Invariant NKT cells rapidly activated via immunization with diverse contact antigens collaborate in vitro with B-1 cells to initiate contact sensitivity. J Immunol, 2006; 177:3686–3694.
9.
DenizG, van de VeenW, AkdisM. Natural killer cells in patients with allergic diseases. J Allergy Clin Immunol, 2013; 132:527–535.
10.
GoebelerM, TrautmannA, VossA, et al.Differential and sequential expression of multiple chemokines during elicitation of allergic contact hypersensitivity. Am J Pathol, 2001; 158:431–440.
11.
DearmanRJ, KimberI. Role of CD4(+) T helper 2–type cells in cutaneous inflammatory responses induced by fluorescein isothiocyanate. Immunology, 2000; 101:442–451.
12.
MinangJT, ArestromI, Troye-BlombergM, et al.Nickel, cobalt, chromium, palladium and gold induce a mixed TH1- and TH2-type cytokine response in vitro in subjects with contact allergy to the respective metals. Clin Exp Immunol, 2006; 146:417–426.
13.
LiuJ, HarbertsE, TammaroA, et al.IL-9 regulates allergen-specific TH1 responses in allergic contact dermatitis. J Invest Dermatol, 2014; 134:1903–1911.
14.
BonecchiR, BianchiG, BordignonPP, et al.Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (TH1s) and TH2s. J Exp Med, 1998; 187:129–134.
15.
MartinSF. T lymphocyte-mediated immune responses to chemical haptens and metal ions: implications for allergic and autoimmune disease. Int Arch Allergy Immunol, 2004; 134:186–198.
16.
CherniakovIN, MaksimovIV, GlazkovaVA. Prevention of altitude decompression sickness during short flights in a depressurized cabin at high altitudes [in Russian]. Kosm Biol Aviakosm Med, 1977; 11:63–67.
17.
WeltzienHU, MoulonC, MartinS, et al.T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology, 1996; 107:141–151.
18.
von BoninA, PlagaS, RuhH, et al.Analysis of major histocompatibility complex class I–restricted hapten recognition by mutation of the V-J joining of T cell receptor alpha chains. Eur J Immunol, 1996; 26:179–186.
19.
NovakN, BaurechtH, SchäferT, et al.Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol, 2008; 128:1430–1435.
20.
SchmidtM, RaghavanB, MüllerV, et al.Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol, 2010; 11:814–819.
21.
BasketterD, Dooms-GoossensA, KarlbergAT, et al.The chemistry of contact allergy: why is a molecule allergenic?. Contact Dermatitis, 1995; 32:65–73.
22.
JoyNM, RiceKR, AtwaterAR. Stability of patch test allergens. Dermatitis, 2013; 24:227–236.
23.
VocansonM, HenninoA, RozieresA, et al.Effector and regulatory mechanisms in allergic contact dermatitis. Allergy, 2009; 64:1699–1714.
24.
RingS, SchaferSC, MahnkeK, et al.CD4+ CD25+ regulatory T cells suppress contact hypersensitivity reactions by blocking influx of effector T cells into inflamed tissue. Eur J Immunol, 2006; 36:2981–2992.
WendtE, WhiteGE, FerryH, et al.Glucocorticoids suppress CCR9-mediated chemotaxis, calcium flux, and adhesion to MAdCAM-1 in human T cells. J Immunol, 2016; 196:3910–3919.
BachelerieF, Ben-BaruchA, BurkhardtAM, et al.International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev, 2014; 66:1–79.
29.
TensenCP, FlierJ, Van Der Raaij-HelmerEM, et al.Human IP-9: a keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol, 1999; 112:716–722.
30.
Sánchez-SánchezN, Riol-BlancoL, de la RosaG, et al.Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood, 2004; 104:619–625.
31.
EscribanoC, Delgado-MartinC, Rodriguez-FernandezJL. CCR7-dependent stimulation of survival in dendritic cells involves inhibition of GSK3beta. J Immunol, 2009; 183:6282–6295.
32.
SantosR, UrsuO, GaultonA, et al.A comprehensive map of molecular drug targets. Nat Rev Drug Discov, 2017; 16:19–34.
33.
KoelinkPJ, OverbeekSA, BraberS, et al.Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther, 2012; 133:1–18.
34.
WhiteGE, IqbalAJ, GreavesDR. CC chemokine receptors and chronic inflammation—therapeutic opportunities and pharmacological challenges. Pharmacol Rev, 2013; 65:47–89.
35.
ColvinRA, CampanellaGS, SunJ, et al.Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem, 2004; 279:30219–30227.
KohoutTA, NicholasSL, PerrySJ, et al.Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem, 2004; 279:23214–23222.
38.
ZidarDA, ViolinJD, WhalenEJ, et al.Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci U S A, 2009; 106:9649–9654.
39.
SmithJS, LefkowitzRJ, RajagopalS. Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov, 2018; 17:243–260.
40.
UrbanJD, ClarkeWP, von ZastrowM, et al.Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther, 2007; 320:1–13.
41.
FlierJ, BoorsmaDM, BruynzeelDP, et al.The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. J Invest Dermatol, 1999; 113:574–578.
42.
KuHO, JeongSH, KangHG, et al.Gene expression profiles and pathways in skin inflammation induced by three different sensitizers and an irritant. Toxicol Lett, 2009; 190:231–237.
43.
EnkAH, KatzSI. Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci U S A, 1992; 89:1398–1402.
44.
CarboneT, NasorriF, PenninoD, et al.CD56highCD16−CD62L− NK cells accumulate in allergic contact dermatitis and contribute to the expression of allergic responses. J Immunol, 2010; 184:1102–1110.
45.
KishDD, GorbachevAV, ParameswaranN, et al.Neutrophil expression of Fas ligand and perforin directs effector CD8 T cell infiltration into antigen-challenged skin. J Immunol, 2012; 189:2191–2202.
46.
SebastianiS, AlbanesiC, DePO, et al.The role of chemokines in allergic contact dermatitis. Arch Dermatol Res, 2002; 293:552–559.
47.
SebastianiS, AlbanesiC, NasorriF, et al.Nickel-specific CD4(+) and CD8(+) T cells display distinct migratory responses to chemokines produced during allergic contact dermatitis. J Invest Dermatol, 2002; 118:1052–1058.
48.
LehtoM, KoivuluhtaM, WangG, et al.Epicutaneous natural rubber latex sensitization induces T helper 2-type dermatitis and strong prohevein-specific IgE response. J Invest Dermatol, 2003; 120:633–640.
49.
MellerS, LauermaAI, KoppFM, et al.Chemokine responses distinguish chemical-induced allergic from irritant skin inflammation: memory T cells make the difference. J Allergy Clin Immunol, 2007; 119:1470–1480.
50.
MartinAP, GagliardiJ, Baena-CagnaniCE, et al.Expression of CS-1 fibronectin precedes monocyte chemoattractant protein-1 production during elicitation of allergic contact dermatitis. Clin Exp Allergy, 2003; 33:1118–1124.
51.
WangHW, TedlaN, LloydAR, et al.Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J Clin Invest, 1998; 102:1617–1626.
52.
YingS, MengQ, BarataLT, et al.Macrophage inflammatory protein-1alpha and C-C chemokine receptor-1 in allergen-induced skin late-phase reactions: relationship to macrophages, neutrophils, basophils, eosinophils and T lymphocytes. Clin Exp Allergy, 2001; 31:1724–1731.
53.
BaumerW, SeegersU, BraunM, et al.TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis. Effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines. Br J Dermatol, 2004; 151:823–830.
54.
CanaveseM, AltrudaF, SilengoL. Therapeutic efficacy and immunological response of CCL5 antagonists in models of contact skin reaction. PLoS One, 2010; 5:e8725.
55.
KusumotoM, XuB, ShiM, et al.Expression of chemokine receptor CCR4 and its ligands (CCL17 and CCL22) in murine contact hypersensitivity. J Interferon Cytokine Res, 2007; 27:901–910.
56.
KamsteegM, JansenPA, van Vlijmen-WillemsIM, et al.Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. Br J Dermatol, 2010; 162:568–578.
57.
TsunemiY, SaekiH, NakamuraK, et al.CCL17 transgenic mice show an enhanced TH2-type response to both allergic and non-allergic stimuli. Eur J Immunol, 2006; 36:2116–2127.
58.
TokurikiA, SeoN, ItoT, et al.Dominant expression of CXCR3 is associated with induced expression of IP-10 at hapten-challenged sites of murine contact hypersensitivity: a possible role for interferon-gamma–producing CD8(+) T cells in IP-10 expression. J Dermatol Sci, 2002; 28:234–241.
59.
SmithJS, RajagopalS. The β-arrestins: multifunctional regulators of G protein–coupled receptors. J Biol Chem, 2016; 291:8969–8977.
60.
RajagopalS, BassoniDL, CampbellJJ, et al.Biased agonism as a mechanism for differential signaling by chemokine receptors. J Biol Chem, 2013; 288:35039–35048.
BerchicheYA, SakmarTP. CXC chemokine receptor 3 alternative splice variants selectively activate different signaling pathways. Mol Pharmacol, 2016; 90:483–495.
63.
SmithJS, NicholsonLT, SuwanpradidJ, et al.Biased agonists differentially control chemotaxis and inflammation at the chemokine receptor CXCR3. Sci Signal In press.
64.
ZoharY, WildbaumG, NovakR, et al.CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest, 2014; 124:2009–2022.
65.
KarinN, WildbaumG, ThelenM. Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets. J Leukoc Biol, 2016; 99:857–862.
CampbellJJ, HaraldsenG, PanJ, et al.The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature, 1999; 400:776–780.
68.
RiisJL, JohansenC, VestergaardC, et al.Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis. Exp Dermatol, 2011; 20:789–794.
69.
ImaiT, NagiraM, TakagiS, et al.Selective recruitment of CCR4-bearing TH2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol, 1999; 11:81–88.
70.
JuSM, SongHY, LeeSJ, et al.Suppression of thymus- and activation-regulated chemokine (TARC/CCL17) production by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose via blockade of NF-kappaB and STAT1 activation in the HaCaT cells. Biochem Biophys Res Commun, 2009; 387:115–120.
71.
StutteS, QuastT, GerbitzkiN, et al.Requirement of CCL17 for CCR7- and CXCR4-dependent migration of cutaneous dendritic cells. Proc Natl Acad Sci U S A, 2010; 107:8736–8741.
72.
KakinumaT, NakamuraK, WakugawaM, et al.Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol, 2001; 107:535–541.
73.
LehtimakiS, TillanderS, PuustinenA, et al.Absence of CCR4 exacerbates skin inflammation in an oxazolone-induced contact hypersensitivity model. J Invest Dermatol, 2010; 130:2743–2751.
74.
WerfelT, HentschelM, KappA, et al.Dichotomy of blood- and skin-derived IL-4–producing allergen-specific T cells and restricted V beta repertoire in nickel-mediated contact dermatitis. J Immunol, 1997; 158:2500–2505.
75.
MoedH, BoorsmaDM, StoofTJ, et al.Nickel-responding T cells are CD4+ CLA+ CD45RO+ and express chemokine receptors CXCR3, CCR4 and CCR10. Br J Dermatol, 2004; 151:32–41.
76.
OuwehandK, ScheperRJ, de GruijlTD, et al.Epidermis-to-dermis migration of immature Langerhans cells upon topical irritant exposure is dependent on CCL2 and CCL5. Eur J Immunol, 2010; 40:2026–2034.
77.
HuttenrauchF, NitzkiA, LinFT, et al.Beta-arrestin binding to CC chemokine receptor 5 requires multiple C-terminal receptor phosphorylation sites and involves a conserved Asp-Arg-Tyr sequence motif. J Biol Chem, 2002; 277:30769–30777.
78.
CorbisierJ, GalesC, HuszaghA, et al.Biased signaling at chemokine receptors. J Biol Chem, 2015; 290:9542–9554.
79.
OgilvieP, BardiG, Clark-LewisI, et al.Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood, 2001; 97:1920–1924.
80.
SallustoF, MackayCR, LanzavecchiaA. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science, 1997; 277:2005–2007.
81.
SchmidCL, KennedyNM, RossNC, et al.Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell, 2017; 171:1165.e13–1175.e13.
82.
SoergelDG, SubachRA, BurnhamN, et al.Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain, 2014; 155:1829–1835.
